Dr. Erika Maestas

Claim this profile

University of New Mexico Cancer Center

Studies Breast Cancer
Studies Esophageal Cancer
4 reported clinical trials
8 drugs studied

Area of expertise

1Breast Cancer
Erika Maestas has run 2 trials for Breast Cancer. Some of their research focus areas include:
p16 positive
p16 negative
BRCA1 positive
2Esophageal Cancer
Erika Maestas has run 2 trials for Esophageal Cancer. Some of their research focus areas include:
Stage IV
BRCA1 positive
BRCA2 positive

Affiliated Hospitals

Image of trial facility.
University Of New Mexico Cancer Center

Clinical Trials Erika Maestas is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Olaparib

for Pancreatic Cancer

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria

More about Erika Maestas

Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Erika Maestas has experience with
  • Olaparib
  • Cisplatin
  • Radiation Therapy
  • MFOLFIRINOX
  • MFOLFOX
  • Nivolumab
Breakdown of trials Erika Maestas has run
Breast Cancer
Esophageal Cancer
Lung Carcinoma
Acinic Cell Carcinoma
Pancreatic Cancer

Other Doctors you might be interested in

Ian RabinowitzLovelace Medical Center-Downtown
Neda Hashemi SadraeiUniversity of New Mexico Comprehensive Cancer Center
Carolyn Y. MullerUniversity of New Mexico

Frequently asked questions

Do I need insurance to participate in a trial?
What does Erika Maestas specialize in?
Is Erika Maestas currently recruiting for clinical trials?
Are there any treatments that Erika Maestas has studied deeply?
What is the best way to schedule an appointment with Erika Maestas?
What is the office address of Erika Maestas?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security